ICG-001
- ICG001；ICG 001
货号： abs810420
| 货号-规格 | 货期 | 价格 | 数量 |
| abs810420-5mg | 1-2周 | ￥857.00 | - + |
| abs810420-10mg | 现货 | ￥1541.00 | - + |
| abs810420-50mg | 现货 | ￥4744.00 | - + |
| abs810420-100mg | 现货 | ￥7610.00 | - + |
大包装询价| 产品描述 | ||
| 描述 | ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro | |
| 纯度 | >98% | |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. | |
| 基本信息 | ||
| 别名 | ICG001；ICG 001 | |
| 外观 | Off-white powder | |
| 可溶性/溶解性 | DMSO ：100 mg/mL (182.27 mM) Ethanol ：10 mg/mL (18.22 mM) | |
| 生物活性 | ||
| 靶点 | Wnt/β-catenin | |
| In vitro(体外研究) | PRI-724 binds specifically to CBP but not the related transcriptional coactivator p300, thereby disrupting the interaction of CBP with β-catenin. Treatment with PRI-724 selectively induces apoptosis in colon carcinoma cells but not in normal colonic epithelial cells and reduces in vitro growth of colon carcinoma cells. | |
| In vivo(体内研究) | PRI-724 exhibits antitumor activity in the mouse xenograft models of colon cancer. The initial results of the Phase I clinic trial of PRI-724 has been disclosed publically. The drug exhibits an acceptable toxicity profile with only one dose-limiting toxicity of grade 3 reversible hyperbilirubinaemia. An Open-Label dose-escalation phase I/II study of PRI-724 for patients with advanced myeloid malignancies is still ongoing. | |
| 温馨提示：本产品仅作科研实验使用，不支持临床等研究 |
- 实验方法 实验条件
共 0张，还能上传 8张 提交
- 提示： 尊敬的客户您好，如果您对我们的产品有什么疑问或想要了解的，可以点击“我要提问”按钮填写您的疑问。
提交不成功？请联系info@absin.cn。
Certificate of Analysis(COA)
